Department of Medical Oncology, Box Hill and Maroondah Hospitals, Maroondah Breast Clinic, 20 Grey St, Ringwood East, Melbourne, VIC 3135, Australia.
Breast. 2011 Oct;20(5):394-406. doi: 10.1016/j.breast.2011.06.004. Epub 2011 Aug 11.
Monotherapy with nanoparticle albumin-bound (nab)-paclitaxel has demonstrated improved efficacy and safety compared with solvent-based paclitaxel and docetaxel.
A comprehensive review of all reported studies of nab-paclitaxel combinations with other agents in all breast cancer settings was undertaken.
Most studies reviewed are small, phase II and non-comparative. Combinations studied included nab-paclitaxel plus trastuzumab and/or bevacizumab (with or without additional cytotoxic agents), gemcitabine, capecitabine, carboplatin, or lapatinib. The majority of metastatic and neoadjuvant studies demonstrated satisfactory efficacy and safety for nab-paclitaxel combinations, although conclusions regarding comparison with solvent-based taxane (SBT) regimens are not possible. The two adjuvant studies confirmed the safety of nab-paclitaxel combinations in this setting.
Although results of this review indicate that nab-paclitaxel may be an appropriate substitute for SBTs in combination regimens, additional research is required to confirm the place and cost effectiveness of these combinations before nab-paclitaxel could be recommended routinely in all settings.
与溶剂型紫杉醇和多西紫杉醇相比，纳米白蛋白结合紫杉醇（nab-紫杉醇）单药治疗显示出更好的疗效和安全性。
对所有报告的nab-紫杉醇联合其他药物在所有乳腺癌治疗环境中的研究进行了全面回顾。
大多数回顾的研究规模较小，为 II 期和非对照研究。研究的联合用药包括 nab-紫杉醇加曲妥珠单抗和/或贝伐单抗（有或无其他细胞毒性药物）、吉西他滨、卡培他滨、卡铂或拉帕替尼。大多数转移性和新辅助研究显示 nab-紫杉醇联合用药具有令人满意的疗效和安全性，尽管无法得出与溶剂型紫杉醇（SBT）方案比较的结论。两项辅助研究证实了 nab-紫杉醇联合用药在该环境下的安全性。
尽管本综述的结果表明，nab-紫杉醇可能是联合治疗方案中 SBT 的合适替代品，但在推荐 nab-紫杉醇在所有情况下常规使用之前，需要进一步研究来确认这些联合用药的地位和成本效益。
